Floatz logo

Zanidatamab

NSCLC (Non-small Cell Lung Cancer)

UNICANCERmonoclonal_antibodyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the NSCLC (Non-small Cell Lung Cancer) cohort.

Asset / SponsorPhaseRating
ose2101
OSE Immunotherapeutics
Phase 3B
Whole Agonist-Stimulated T Cells
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
OSE-279
OSE Immunotherapeutics
Phase 1/2CC
yh42946
Yuhan Corporation
Phase 1/2CC
Part A: Ose-279
OSE Immunotherapeutics
Phase 1/2CC

View all 11 →

Same molecule, other indications

Zanidatamab is also rated in:

HER2 positive breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
HER2 Low Breast CarcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →